April 2021 – Page 2 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2021-04-20

COVID-19 Vaccine J&J: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets but confirms overall benefit-risk remains positive.

At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC also concluded that these events should be listed as very rare side effects of the vaccine. In reaching its conclusion, the Committee took into

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-20

The Lernaean Hydra of post Covid-19 Vaccine Blood Clotting

For weeks, Americans looked on as other countries grappled with case reports of rare, sometimes fatal blood abnormalities among those who had received the AstraZeneca vaccine against COVID-19. That vaccine has not yet been authorized by the FDA, so restrictions on its use throughout Europe did not get that much attention in the United States.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-17

3D-Bioprinting in precision medicine: regenerative cell therapy and drug testing

Precision medicine is, broadly speaking, a sweeping aspiration that will be achieved, or not, depending on the convergence of many different disciplines. The most important of these disciplines are molecular genetics and cell biology. Besides contributing to precision medicine directly, they also contribute through 3D bioprinting. In 3D bioprinting, molecular genetics and cell biology are

No Comments InBIOPRINTING

PIER MARIA FORNASARI
2021-04-16

In a new paper on NEJM Pathologic Antibodies to Platelet Factor 4 were found after AstraZeneca Covid Vaccine

The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity. In this paper are reported findings in 23 patients who presented with

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-16

Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Non pharmaceutical interventions have a higher effect on the epidemic evolution than vaccination alone.

Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19), population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model, which predicts the spread of SARS-CoV-2 infections, with a newdata-based model that projects new

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-16

For a report published by University of Oxford risk of rare blood clotting is 10 times higher for COVID-19 than for vaccines. CVST incidence is 4 for Pfizer and 5 cases per milion doses for AstraZeneca.

Researchers at the University of Oxford have today reported that the risk of the rare blood clotting known as cerebral venous thrombosis (CVT) following COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza. The study authors, led by Professor Paul Harrison and Dr Maxime Taquet

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-15

Risdiplam improves motor function and survival in infants with SMA

PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial of Evrysdi (risdiplam), which demonstrated that infants with type 1 spinal muscular atrophy (SMA) continued to show improvements in survival and key motor milestones after two years of treatment. PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2021-04-15

South Africa SARS-CoV-2 variant B.1.351 easily evades Sputnik vaccine

The use of this vaccine in several countries in South America and eastern Europe, besides Russia, mandates that its efficacy against the new resistant variants be tested, as they are being found more commonly in these regions.Generation of replication-competent VSV bearing SARS-CoV-2 spike (rcVSV-CoV2-S). (A) Schematic of the rcVSV-CoV2-S genomic coding construct and the virus

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-13

New Technique Provides Detailed Map of Lung Pathology in COVID-19. Disease progression may not depend on the persistence of the virus, but on an overreaction of the immune system.

A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases. In the study, published online March 29 in Nature, the researchers imaged autopsied lung tissue in a way that

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-13

What is Cerebral Venous Sinus Thrombosis (CVST), the post adenovirus Covid-19 vaccine rare clotting complication: Vaccine Immune Thrombotic Thrombocytopenia represents a small percent of cases. Need to define other cases diagnosis and treatment.

Cerebral venous sinus thrombosis (CVST) occurs when a blood clot forms in the brain’s venous sinuses. This prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage. This chain of events is part of a stroke that can occur in adults

No Comments InCovid-19

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Archives: 2021-04-20

COVID-19 Vaccine J&J: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets but confirms overall benefit-risk remains positive.

The Lernaean Hydra of post Covid-19 Vaccine Blood Clotting

3D-Bioprinting in precision medicine: regenerative cell therapy and drug testing

In a new paper on NEJM Pathologic Antibodies to Platelet Factor 4 were found after AstraZeneca Covid Vaccine

Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Non pharmaceutical interventions have a higher effect on the epidemic evolution than vaccination alone.

For a report published by University of Oxford risk of rare blood clotting is 10 times higher for COVID-19 than for vaccines. CVST incidence is 4 for Pfizer and 5 cases per milion doses for AstraZeneca.

Risdiplam improves motor function and survival in infants with SMA

South Africa SARS-CoV-2 variant B.1.351 easily evades Sputnik vaccine

New Technique Provides Detailed Map of Lung Pathology in COVID-19. Disease progression may not depend on the persistence of the virus, but on an overreaction of the immune system.

What is Cerebral Venous Sinus Thrombosis (CVST), the post adenovirus Covid-19 vaccine rare clotting complication: Vaccine Immune Thrombotic Thrombocytopenia represents a small percent of cases. Need to define other cases diagnosis and treatment.